With a new production unit opened in 2021 and a production capacity 3 times larger, Biofarm aims for a 15% increase in turnover and a 7% increase in profit for the current year.

Regarding the Biofarm shares, listed on the stock exchange since 1996, their price has increased constantly in the last 5 years, from 0.2500 lei / share in 2016 to 0.5600 lei / share at the end of the first quarter of this year. The price is constantly increasing, exceeding the threshold of 0.6000 lei / share in the first week of May.

In the context of an accelerated decrease in the Consumer Healthcare (CHC) category both in value (-64.5 million RON) and in units (-9.7 million UC), Biofarm consolidates its leadership in terms of value, at the purchase price in pharmacies, with a 3.2% increase and ends the first quarter on the 3rd place in the top companies in the local pharmaceutical industry in this category.

Biofarm brands maintain their position as market leader in terms of consumption. These recorded significant increases in MoH and contributed to maintaining the market leader position in 7 categories.

"Despite the decline in the CHC segment, we started 2021 with remarkable results. We aim at a sustained increase of the market share throughout the year and we continue to streamline operations and consolidate the competitive advantage of the product portfolio” said Cătălin Vicol, General Manager of Biofarm.

Biofarm has always focused its actions on developing products to the highest standards to meet the needs of consumers. The manufacturer celebrates 100 years of activity this year, and the company's expertise and product quality, in a continuous process of innovation, have contributed to positioning Biofarm as an important player in the competitive context of the Romanian pharmaceutical industry.

The Biofarm portfolio still includes products that have passed the test of time, such as Carmol, on the market since 1928, Triferment and Anghirol, two of the best known brands, launched in 1959, Cavit, essential in the harmonious development of children, appeared in 1964, or Colebil, the biliary problems expert who is still the market leader today, more than 50 years after its appearance.

Biofarm continues to prove that it is a visionary company that leaves its mark on the way it does business, the way it relates to employees, the way it supports the well-being of patients and the way the pharmaceutical history of Romania is written.